Ocular responses in healthy subjects to topical bunazosin 0.3%--an alpha 1-adrenoceptor antagonist.
The ocular effects of the alpha-adrenoceptor blocking drug bunazosin, administered as eyedrops, have been measured in a placebo-controlled double-blind single-dose study in 15 healthy volunteers. The drug significantly reduced intraocular pressure over 10 hours, and there was no associated change in pulsatile ocular blood flow. Characteristic effects of alpha-adrenoceptor blockade were observed--miosis, ptosis, and conjunctival hyperaemia. The miosis alone persisted for more than 24 hours in nine out of 15 subjects.
Division of Pharmacological Sciences and Toxicology, United Medical School, London.
D R
DR
Trew
L A
LA
Wright
S E
SE
Smith
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D000328:Adult; D004311:Double-Blind Method; D005123:Eye / Q000098:blood supply*; D005143:Eyelids / Q000187:drug effects; D005260:Female; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011680:Pupil / Q000187:drug effects; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*
D000317:Adrenergic alpha-Antagonists; D009883:Ophthalmic Solutions; D011799:Quinazolines; C018176:bunazosin